164 related articles for article (PubMed ID: 19212667)
1. The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses.
Schmitt A; Barth TF; Beyer E; Borchert F; Rojewski M; Chen J; Guillaume P; Gronau S; Greiner J; Möller P; Riechelmann H; Schmitt M
Int J Oncol; 2009 Mar; 34(3):629-39. PubMed ID: 19212667
[TBL] [Abstract][Full Text] [Related]
2. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.
Giannopoulos K; Li L; Bojarska-Junak A; Rolinski J; Dmoszynska A; Hus I; Greiner J; Renner C; Döhner H; Schmitt M
Int J Oncol; 2006 Jul; 29(1):95-103. PubMed ID: 16773189
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
[TBL] [Abstract][Full Text] [Related]
5. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
Giannopoulos K; Dmoszynska A; Kowal M; Rolinski J; Gostick E; Price DA; Greiner J; Rojewski M; Stilgenbauer S; Döhner H; Schmitt M
Leukemia; 2010 Apr; 24(4):798-805. PubMed ID: 20220777
[TBL] [Abstract][Full Text] [Related]
6. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.
Greiner J; Ringhoffer M; Taniguchi M; Schmitt A; Kirchner D; Krähn G; Heilmann V; Gschwend J; Bergmann L; Döhner H; Schmitt M
Exp Hematol; 2002 Sep; 30(9):1029-35. PubMed ID: 12225794
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Meier C; Schmitt A; Spitschak A; Hilgendorf I; Rohde S; Hirt C; Freund M; Pützer BM; Schmitt M
Clin Dev Immunol; 2012; 2012():146463. PubMed ID: 22719778
[TBL] [Abstract][Full Text] [Related]
8. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
[TBL] [Abstract][Full Text] [Related]
9. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.
Schmitt M; Schmitt A; Rojewski MT; Chen J; Giannopoulos K; Fei F; Yu Y; Götz M; Heyduk M; Ritter G; Speiser DE; Gnjatic S; Guillaume P; Ringhoffer M; Schlenk RF; Liebisch P; Bunjes D; Shiku H; Dohner H; Greiner J
Blood; 2008 Feb; 111(3):1357-65. PubMed ID: 17978170
[TBL] [Abstract][Full Text] [Related]
10. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck.
Visus C; Ito D; Amoscato A; Maciejewska-Franczak M; Abdelsalem A; Dhir R; Shin DM; Donnenberg VS; Whiteside TL; DeLeo AB
Cancer Res; 2007 Nov; 67(21):10538-45. PubMed ID: 17974998
[TBL] [Abstract][Full Text] [Related]
11. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
12. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
Babiak A; Steinhauser M; Götz M; Herbst C; Döhner H; Greiner J
Oncol Rep; 2014 Jan; 31(1):384-90. PubMed ID: 24154794
[TBL] [Abstract][Full Text] [Related]
13. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
14. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.
Chen J; Schmitt A; Bunjes D; Chen B; Schmitt M
Int J Oncol; 2007 May; 30(5):1119-27. PubMed ID: 17390013
[TBL] [Abstract][Full Text] [Related]
15. Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.
Albers AE; Qian X; Kaufmann AM; Mytilineos D; Ferris RL; Hoffmann TK; DeLeo AB
Sci Rep; 2018 Jul; 8(1):10716. PubMed ID: 30013227
[TBL] [Abstract][Full Text] [Related]
16. EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma.
Schuler PJ; Boeckers P; Engers R; Boelke E; Bas M; Greve J; Dumitru CA; Lehnerdt GF; Ferris RL; Andrade Filho PA; Brandau S; Lang S; Whiteside TL; Hoffmann TK
J Transl Med; 2011 Oct; 9():168. PubMed ID: 21970318
[TBL] [Abstract][Full Text] [Related]
17. Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
Rasmussen S; Donskov F; Pedersen JW; Wandall HH; Buus S; Harndahl M; Braendstrup P; Claesson MH; Pedersen AE
Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):487-96. PubMed ID: 23802595
[TBL] [Abstract][Full Text] [Related]
18. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.
Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN
Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531
[TBL] [Abstract][Full Text] [Related]
19. p53 as an immunotherapeutic target in head and neck cancer.
Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
[TBL] [Abstract][Full Text] [Related]
20. Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.
Visus C; Ito D; Dhir R; Szczepanski MJ; Chang YJ; Latimer JJ; Grant SG; DeLeo AB
Cancer Immunol Immunother; 2011 Jul; 60(7):919-29. PubMed ID: 21409596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
